ARS PHARMACEUTICALS INC (SPRY) Stock Analyst Earnings Estimates
NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.32M | 30K -97.73% | 18.4M 61,233.33% | 126.09M 585.27% | 225.7M 79.00% | 314.55M 39.37% | 494.73M 57.28% | 637.87M 28.93% | 788.81M 23.66% | 946.78M 20.03% | 751.21M -20.66% | ||
| EBITDA YoY % growth | -88.8M -175.09% | -35.2M 60.36% | -67.447M -91.61% | -26.306M 61.00% | -49.558M -88.39% | 109.7M 321.36% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -89.58M -172.11% | -35.52M 60.35% | -67.52M -90.09% | -69.099M -2.34% | -40.772M 40.99% | 12.918M 131.68% | 50.031M 287.30% | 174.77M 249.32% | 293.91M 68.17% | 415.46M 41.36% | 523.85M 26.09% | 417.38M -20.32% | |
| Operating Margin | N/A | -2,690.91% | -225,066.67% | -375.54% | -32.34% | 5.72% | 15.91% | 35.33% | 46.08% | 52.67% | 55.33% | 55.56% | |
| EPS YoY % growth | -2.56 -10.08% | -0.98 61.72% | -0.57 41.84% | -0.59 -3.34% | -0.36 38.96% | 0.05 114.18% | 0.47 830.00% | 1.34 182.80% | 2.06 53.61% | 3.15 52.97% | 4.25 34.95% | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 -100.36% | -0.19 -69.23% | -0.21 -58.88% | -0.03 84.70% | 0.05 138.18% | -0.07 61.64% | 0.19 193.83% | 0.48 1,666.67% | 0.29 433.33% |
| Revenue Q2Q % growth | 17.927M | 15.02M | 16.628M 3,225.60% | 44.883M 2,070.36% | 49.248M 174.71% | 40.882M 172.18% | 72.95M 338.72% | 111.08M 147.49% | 85.007M 72.61% |
| EBITDA Q2Q % growth | 24.929M 345.53% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.826M -64.54% | -19.029M -44.25% | -23.616M -53.95% | -2.149M 90.12% | 4.263M 125.34% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.20 -25.00% | -0.15 | -0.05 | -32.93% |
| Q2 2024 Q2Q % growth | -0.13 27.78% | -0.12 | -0.01 | -9.24% |
| Q1 2024 Q2Q % growth | -0.11 31.25% | -0.11 | 0.00 | 1.96% |
| Q4 2023 Q2Q % growth | -0.07 -109.09% | -0.14 | 0.07 | 50.98% |
| Q3 2023 Q2Q % growth | -0.16 68.00% | -0.19 | 0.03 | 14.13% |
| Q2 2023 Q2Q % growth | -0.18 67.27% | -0.18 | 0.00 | -1.61% |
| Q1 2023 Q2Q % growth | -0.16 77.14% | -0.17 | 0.01 | 6.45% |
| Q4 2022 Q2Q % growth | 0.77 214.93% | -0.13 | 0.90 | 680.69% |
| Q3 2022 Q2Q % growth | -0.50 23.08% | -0.36 | -0.14 | -38.08% |
| Q2 2022 Q2Q % growth | -0.55 21.43% | -0.49 | -0.06 | -11.56% |
| Q1 2022 Q2Q % growth | -0.70 -29.63% | -0.55 | -0.15 | -28.04% |
| Q4 2021 Q2Q % growth | -0.67 51.09% | -0.72 | 0.05 | 6.43% |
| Q3 2021 Q2Q % growth | -0.65 | -0.69 | 0.04 | 5.45% |
| Q2 2021 Q2Q % growth | -0.70 | -0.54 | -0.16 | -28.68% |
| Q1 2021 Q2Q % growth | -0.54 | -0.36 | -0.18 | -49.13% |
| Q4 2020 Q2Q % growth | -1.37 | -0.50 | -0.87 | -174.11% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.068M | 586.5K | 1.482M | 252.60% |
| Q2 2024 Q2Q % growth | 500K 4,900.00% | 1.02M | -520K | -50.98% |
| Q1 2024 Q2Q % growth | -100.00% | % | ||
| Q4 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | 1.32M | 96.39K | 1.224M | 1,269.44% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -103.7% | 12.7% | 0.86% | 10.12% |
| Revenue | -31.02% | 4.88% | -9.09% | 181.52% |